Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Berkeley Lights' CEO Eric Hobbs Speaks to The Future of Cell-based Products and Therapeutics in Presentation at Annual J.P. Morgan Healthcare Conference | ||
By: PR Newswire Association LLC. - 16 Jan 2020 | Back to overview list |
|
SAN FRANCISCO, Jan. 16, 2020 /PRNewswire/ -- Eric Hobbs, Ph.D., CEO of Berkeley Lights, spoke at the annual J.P. Morgan Healthcare Conference on Tuesday to a fully-packed room of industry leaders and the investment community about Berkeley Lights' technology, vision for the future, and upcoming products. The excitement around the impact Berkeley Lights is making in the scientific community was incredibly energizing. "At Berkeley Lights, we've created advanced environments for functionally testing live cells to accelerate the discovery and development of cell-based products," said Dr. Hobbs. "We do it in a fast, repeatable and automated way, at all points in the discovery process, giving our customers the highest probability of selecting the best cells to create a cell-based product and the shortest time to biologic product and revenue. And how we do it is that we capture and interpret the qualitative language of biology, both phenotypic and genomic information, on a single cell level, and translate it into digital information. Berkeley Lights is the only company with a platform that can do this in a scalable way." Launched in 2016, Berkeley Lights' Beacon® Optofluidic Platform has installations at 50% of the top 25 Pharma companies and is currently working with leading cancer centers and top synthetic biology companies. The company operates at the intersection of biology, technology, and information. Light and semiconductor technology are combined in a nanofluidic environment to move single cells into isolated pens for culture, assay and live cell export. "Our mission is to accelerate the use of cell-based products across a wide range of multiple billion dollar markets. We believe the vast majority of biology can be processed on Berkeley Lights' solutions, therefore enabling all scientists and researchers to find the best cell or organism in each application they serve," said Dr. Hobbs. About Berkeley Lights Berkeley Lights' opto-fluidic platforms are: For Research Use Only. Not for use in diagnostic procedures. View original content to download multimedia:http://www.prnewswire.com/news-releases/berkeley-lights-ceo-eric-hobbs-speaks-to-the-future-of-cell-based-products-and-therapeutics-in-presentation-at-annual-jp-morgan-healthcare-conference-300988535.html SOURCE Berkeley Lights |
||
|
||
Copyright 2020 PR Newswire Association LLC. | Back to overview list |